📊 HIMS Key Takeaways
Is Hims & Hers Health, Inc. (HIMS) a Good Investment?
Hims demonstrates impressive 59% revenue growth and maintains a fortress balance sheet with $222.3M cash, zero debt, and positive free cash flow of $53.1M. However, operating losses of $78.3M and negative ROE of -20.6% reflect deteriorating unit economics and unclear path to profitability, requiring proof of operating leverage before upgrading thesis.
Hims & Hers is scaling rapidly with 59% YoY revenue growth and a robust 73.8% gross margin, now translating into positive operating and net income with strong ROE and no leverage. Healthy liquidity and solid operating cash flow support continued investment, but free cash flow remains modest due to heavy capex and diluted EPS; sustained margin expansion and FCF conversion are the keys to durable profitability.
Why Buy Hims & Hers Health, Inc. Stock? HIMS Key Strengths
- Exceptional 59% YoY revenue growth with 65.2% gross margins indicating strong pricing power
- Positive free cash flow of $53.1M and operating cash flow of $89.4M despite net losses
- Fortress balance sheet with zero long-term debt, $222.3M cash, and 1.69x current ratio
- Rapid top-line growth with high gross margin
- Positive profitability with strong ROE and zero debt
- Healthy liquidity and strong operating cash generation
HIMS Stock Risks: Hims & Hers Health, Inc. Investment Risks
- Company unprofitable with -$92.1M net loss and -12.9% operating margin indicating unsustainable cost structure
- Negative returns: ROE of -20.6% and ROA of -4.1% suggest shareholder value destruction at current scale
- Operating expenses consuming 78.1% of revenue despite high gross margins indicates lack of operating leverage
- Thin operating margin and low FCF margin from high capex
- EPS dilution risk (share count/SBC effects)
- Potential growth slowdown if customer acquisition efficiency weakens or regulatory pressure rises
Key Metrics to Watch
- Operating margin trend and timeline to positive GAAP profitability
- Operating expense ratio and progress toward leverage as revenue scales
- Free cash flow sustainability and cash runway relative to burn rate
- Operating margin expansion
- Free cash flow margin (capex intensity)
Hims & Hers Health, Inc. (HIMS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Hims & Hers Health, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
HIMS Profit Margin, ROE & Profitability Analysis
HIMS vs Services Sector: How Hims & Hers Health, Inc. Compares
How Hims & Hers Health, Inc. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Hims & Hers Health, Inc. Stock Overvalued? HIMS Valuation Analysis 2026
Based on fundamental analysis, Hims & Hers Health, Inc. has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Hims & Hers Health, Inc. Balance Sheet: HIMS Debt, Cash & Liquidity
HIMS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Hims & Hers Health, Inc.'s revenue has grown significantly by 763% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.11 indicates the company is currently unprofitable.
HIMS Revenue Growth, EPS Growth & YoY Performance
HIMS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $586.0M | $49.5M | $0.20 |
| Q3 2025 | $401.6M | $11.1M | $0.06 |
| Q2 2025 | $315.6M | $11.1M | $0.06 |
| Q1 2025 | $278.2M | $11.1M | $0.05 |
| Q3 2024 | $226.7M | -$7.2M | $-0.04 |
| Q2 2024 | $207.9M | -$7.2M | $-0.03 |
| Q1 2024 | $190.8M | -$10.1M | $-0.05 |
| Q3 2023 | $144.8M | -$7.2M | $-0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Hims & Hers Health, Inc. Dividends, Buybacks & Capital Allocation
HIMS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Hims & Hers Health, Inc. (CIK: 0001773751)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HIMS
What is the AI rating for HIMS?
Hims & Hers Health, Inc. (HIMS) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are HIMS's key strengths?
Claude: Exceptional 59% YoY revenue growth with 65.2% gross margins indicating strong pricing power. Positive free cash flow of $53.1M and operating cash flow of $89.4M despite net losses. ChatGPT: Rapid top-line growth with high gross margin. Positive profitability with strong ROE and zero debt.
What are the risks of investing in HIMS?
Claude: Company unprofitable with -$92.1M net loss and -12.9% operating margin indicating unsustainable cost structure. Negative returns: ROE of -20.6% and ROA of -4.1% suggest shareholder value destruction at current scale. ChatGPT: Thin operating margin and low FCF margin from high capex. EPS dilution risk (share count/SBC effects).
What is HIMS's revenue and growth?
Hims & Hers Health, Inc. reported revenue of $608.1M.
Does HIMS pay dividends?
Hims & Hers Health, Inc. does not currently pay dividends.
Where can I find HIMS SEC filings?
Official SEC filings for Hims & Hers Health, Inc. (CIK: 0001773751) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HIMS's EPS?
Hims & Hers Health, Inc. has a diluted EPS of $-0.40.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HIMS a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Hims & Hers Health, Inc. has a BUY rating with 72% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is HIMS stock overvalued or undervalued?
Valuation metrics for HIMS: ROE of -20.6% (sector avg: 16%), net margin of -15.1% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy HIMS stock in 2026?
Our dual AI analysis gives Hims & Hers Health, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HIMS's free cash flow?
Hims & Hers Health, Inc.'s operating cash flow is $89.4M, with capital expenditures of $36.3M. FCF margin is 8.7%.
How does HIMS compare to other Services stocks?
Vs Services sector averages: Net margin -15.1% (avg: 10%), ROE -20.6% (avg: 16%), current ratio 1.69 (avg: 1.5).